Adipokines in Non-Alcoholic Fatty Liver Disease: Are We on the Road toward New Biomarkers and Therapeutic Targets?
Year: 2022
Type: review
Abstract: Non-alcoholic fatty liver disease (NAFLD) has become the major cause of chronic hepatic illness and the leading indication for liver transplantation in the future decades. NAFLD is also commonly associated with other high-incident non-communicable diseases, such as cardiovascular complications, type 2 diabetes, and chronic kidney disease. Aggravating the socio-economic impact of this complex pathology, routinely feasible diagnostic methodologies and effective drugs for NAFLD management are unavailable. The pathophysiology of NAFLD, recently defined as metabolic associated fatty liver disease (MAFLD), is correlated with abnormal adipose tissue-liver axis communication because obesity-associated white adipose tissue (WAT) inflammation and metabolic dysfunction prompt hepatic insulin resistance (IR), lipid accumulation (steatosis), non-alcoholic steatohepatitis (NASH), and fibrosis. Accumulating evidence links adipokines, cytokine-like hormones secreted by adipose tissue that have immunometabolic activity, with NAFLD pathogenesis and progression; however, much uncertainty still exists. Here, the current knowledge on the roles of leptin, adiponectin, ghrelin, resistin, retinol-binding protein 4 (RBP4), visfatin, chemerin, and adipocyte fatty-acid-binding protein (AFABP) in NAFLD, taken from preclinical to clinical studies, is overviewed. The effect of therapeutic interventions on adipokines' circulating levels are also covered. Finally, future directions to address the potential of adipokines as therapeutic targets and disease biomarkers for NAFLD are discussed.
Source: Biology
Authors: Vera Francisco(Conceptualization, Data curation, Funding acquisition, Investigation, Project administration, Writing – original draft, Writing – review & editing), Maria Jesus Sanz(Conceptualization, Funding acquisition, Writing – review & editing), José T. Real(Conceptualization, Funding acquisition, Writing – review & editing), Patrice Marques(Investigation, Writing – review & editing), Maurizio Capuozzo(Investigation), Djedjiga Ait Eldjoudi(Investigation), Oreste Gualillo(Conceptualization, Funding acquisition, Writing – review & editing)
Institutions: Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, Universitat de València, Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas, Instituto de Investigación Sanitaria de Santiago, Servicio Gallego de Salud
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Keywords: non-alcoholic fatty liver disease, adipokines, biomarkers, therapeutic target, leptin, adiponectin, ghrelin, resistin, retinol-binding protein 4, visfatin, chemerin, adipocyte fatty acid-binding protein, hepatic insulin resistance, hepatic steatosis, liver fibrosis, nonalcoholic steatohepatitis, obesity
Open Access status: gold
Estimated APC paid: $2,094
Awards: G1147380508, G1276901954, G165900816, G2219494556, G2283843487, G228988687, G2292337761, G2455723009, G2900408184, G3420160830, G3437564347, G3743139511, G3839426528, G3868185547, G4171396670, G4270759030, Adipokinas y E74-like factor 3 (ELF3): un nuevo circuito en las rutas de señalización de la respuesta inflamatoria en la degeneración del disco intervertebral., G4497745854, G4567191414, G522263893, G5512774623, G6024539900, G6287052183, G6421489960, G6479640224, G6689531355, G7744042362, G8136634338, G8269066876, G8508568521, G859410654, G8604457850, G8830698753, G8835801476, G907696694
OpenAlex ID: W4292547529
